Indivior Pharmaceuticals (INDV) Net Income towards Common Stockholders (2024 - 2026)

Indivior Pharmaceuticals' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at $89.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 85.42% year-over-year to $89.0 million; the TTM figure through Mar 2026 stood at $251.0 million (up 3685.71% YoY), while the FY2025 annual figure was $210.0 million, up 2900.0% from the prior year.
• Net Income towards Common Stockholders was $89.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $102.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $102.0 million in Q4 2025 to a low of -$98.0 million in Q2 2024.
• Historically, Net Income towards Common Stockholders has averaged $34.0 million across 3 years, with a median of $42.0 million in 2025.
• Biggest YoY gain for Net Income towards Common Stockholders was 385.71% in 2025; the steepest drop was 22.58% in 2025.
• A 3-year view of Net Income towards Common Stockholders shows it stood at $21.0 million in 2024, then soared by 385.71% to $102.0 million in 2025, then slipped by 12.75% to $89.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $89.0 million (Q1 2026), $102.0 million (Q4 2025), and $42.0 million (Q3 2025), per Business Quant data.